4 recruiting, 2 active not recruiting, 2 unknown, 1 completed. 10 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Active not recruiting 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow ARX788: new trials by email Literature Review of ARX788 trials Research Report on ARX788
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer ARX788, Computed Tomography (CT), Biospecimen Collection - HER2 Low Breast Carcinoma, Triple Negative Breast Cancer | Phase 2 | Recruiting | Laura Huppert, MD, BA | 36 | 2026-06-05 | 2026-06-11 |
| ARX788 in HER2-positive Metastatic Breast Cancer Patients ARX788 - HER2-positive, Metastatic Breast Cancer | Phase 2 | Recruiting | Henan Cancer Hospital | 44 | 2025-06-16 | 2026-10-16 |
| ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd ARX788 - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 44 | 2024-09-30 | 2024-08-29 |
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients ARX788, Pyrotinib maleate, Trastuzumab - HER2-positive Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Caigang Liu | 136 | 2022-05-23 | 2024-10-30 |
| ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) ARX788 - HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors | Phase 2 | Withdrawn | Ambrx, Inc. | 2021-11-05 | 2022-09-13 | |
| ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) ARX788 - HER2 Positive Metastatic Breast Cancer | Phase 2 | Active not recruiting | Ambrx, Inc. | 72 | 2021-10-26 | 2026-03-09 |
| ARX788 in Breast Cancer With Low Expression of HER2 ARX788 - Breast Cancer With Low Expression of HER2 | Phase 2 | Unknown | Fudan University | 54 | 2021-10-20 | 2022-04-25 |
| Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) - Breast Neoplasms | Phase 2 | Recruiting | Shengjing Hospital | 30 | 2021-08-01 | 2022-09-13 |
| ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases ARX788 - HER2-positive, Metastatic Breast Cancer | Phase 2 | Unknown | Fudan University | 32 | 2021-07-14 | 2022-06-01 |
| A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) ARX788 - Breast Neoplasms, Gastric Neoplasm | Phase 1 | Completed | Ambrx, Inc. | 106 | 2018-03-20 | 2024-02-01 |
| A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression ARX788 - Breast Neoplasms, Stomach Neoplasms | Phase 1 | Terminated | Zhejiang Medicine Co., Ltd. | 9 | 2016-03-01 | 2020-06-05 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
Breast Neoplasms (10) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Hemangiosarcoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pathologic Complete Response (1)
Ambrx, Inc. (3) · Fudan University (3) · Caigang Liu (1) · Henan Cancer Hospital (1) · Laura Huppert, MD, BA (1) · QuantumLeap Healthcare Collaborative (1) · Shengjing Hospital (1) · Zhejiang Medicine Co., Ltd. (1)
China (5) · United States (5) · Australia (3) · New Zealand (1) · South Korea (1)
Cai-Gang Liu (1) · Caigang Liu, MD (1) · Laura Esserman, MD, MBA (1) · Laura Huppert, MD (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41245540, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224